MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation

被引:274
作者
Fujita, N
Jaye, DL
Geigerman, C
Akyildiz, A
Mooney, MR
Boss, JM
Wade, PA [1 ]
机构
[1] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Div Hematopathol, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA
[4] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA
关键词
D O I
10.1016/j.cell.2004.09.014
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The transcriptional repressor BCL-6 regulates B lymphocyte cell fate during the germinal center reaction by preventing terminal differentiation of B lymphocytes into plasma cells until appropriate signals are received. Here, we report a cofactor, MTA3, a cell type-specific subunit of the corepressor complex Mi-2/ NuRD, for BCL-6-dependent cell fate determination. MTA3 is expressed in the same pattern in germinal centers as BCL-6. BCL-6 physically interacts with Mi-2/NuRD and this interaction is sensitive to BCL-6 acetylation status. Depletion of MTA3 by RNAi impairs BCL-6-dependent repression and alters the cell-specific transcriptional pattern characteristic of the B lymphocyte. Remarkably, exogenous expression of BCL-6 in a plasma cell line leads, in an MTA3-dependent manner, to repression of plasma cell-specific transcripts, reactivation of the B cell transcriptional program, expression of B lymphocyte cell surface markers, and reprogramming of cell fate.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 54 条
  • [31] GENERAL CONCLUSIONS - TELEONOMIC MECHANISMS IN CELLULAR METABOLISM, GROWTH, AND DIFFERENTIATION
    MONOD, J
    JACOB, F
    [J]. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1961, 26 : 389 - &
  • [32] Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
    MuhlethalerMOttet, A
    Otten, LA
    Steimle, V
    Mach, B
    [J]. EMBO JOURNAL, 1997, 16 (10) : 2851 - 2860
  • [33] Modulation of gene expression by the MHC class II transactivator
    Nagarajan, UM
    Bushey, A
    Boss, JM
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 169 (09) : 5078 - 5088
  • [34] NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477
  • [35] The proto-oncogene BCL-6 in normal and malignant B cell development
    Niu, HF
    [J]. HEMATOLOGICAL ONCOLOGY, 2002, 20 (04) : 155 - 166
  • [36] BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells
    Piskurich, JF
    Lin, KI
    Lin, Y
    Wang, Y
    Ting, JPY
    Calame, K
    [J]. NATURE IMMUNOLOGY, 2000, 1 (06) : 526 - 532
  • [37] Lymphoid malignancies: The dark side of B-cell differentiation
    Shaffer, AL
    Rosenwald, A
    Staudt, LM
    [J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (12) : 920 - 932
  • [38] BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control
    Shaffer, AL
    Yu, X
    He, YS
    Boldrick, J
    Chan, EP
    Staudt, LM
    [J]. IMMUNITY, 2000, 13 (02) : 199 - 212
  • [39] Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program
    Shaffer, AL
    Lin, KI
    Kuo, TC
    Yu, X
    Hurt, EM
    Rosenwald, A
    Giltnane, JM
    Yang, LM
    Zhao, H
    Calame, K
    Staudt, LM
    [J]. IMMUNITY, 2002, 17 (01) : 51 - 62
  • [40] Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells
    Shapiro-Shelef, M
    Lin, KI
    McHeyzer-Williams, LJ
    Liao, J
    McHeyzer-Williams, MG
    Calame, K
    [J]. IMMUNITY, 2003, 19 (04) : 607 - 620